Genscript BiotechGNNSF 66 Current Ratio is 1.50 as of Dec. 2025, which is 56% below its 10-year median of 3.38. GuruFocus rates GNNSF with a GF Score™ of 66/100 and a GF Value™ of $2.48 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,411 Biotechnology companies, Genscript Biotech ranks worse than 76.05% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Genscript Biotech's current ratio for the quarter that ended in Dec. 2025 was 1.50.
Genscript Biotech has a current ratio of 1.50. It generally indicates good short-term financial strength.
The historical rank and industry rank for Genscript Biotech's Current Ratio or its related term are showing as below:
GNNSF'
s Current Ratio Range Over the Past 10 Years
Min: 1.07 Med: 3.38 Max: 4.76
Current: 1.5
During the past 12 years, Genscript Biotech's highest Current Ratio was 4.76. The lowest was 1.07. And the median was 3.38.
GNNSF's Current Ratio is ranked worse than 76.05% of 1411
companies
in the Biotechnology industry
Industry Median: 3.91
vs GNNSF: 1.50
Genscript Biotech (OTCPK:GNNSF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Genscript Biotech Current Ratio Related Terms
Genscript Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GNNSF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Genscript Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a Current Ratio of 1.50 as of Dec. 2025. This is 56% below median its historical median of 3.38. Over the past decade, Genscript Biotech's Current Ratio has ranged from 1.07 to 4.76. According to the industry distribution chart, Genscript Biotech ranks #1073 out of 1411 companies in the Biotechnology industry, placing it in the top 76%.
Is Genscript Biotech's Current Ratio too high?
Genscript Biotech's current Current Ratio of 1.50 is 56% below median its 10-year median of 3.38. Over the past 10 years, this metric has ranged from a low of 1.07 to a high of 4.76. The Biotechnology industry median Current Ratio is 3.91. Genscript Biotech's value of 1.50 is 61.6% below this industry median. Based on the distribution chart, Genscript Biotech ranks #1073 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genscript Biotech has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #1073 out of 1411 companies for Current Ratio. This places Genscript Biotech in the lower half of its industry. The industry median Current Ratio is 3.91. Genscript Biotech's value of 1.50 is 61.6% below this benchmark. Historically, Genscript Biotech's own Current Ratio has ranged from 1.07 to 4.76 over the past decade. While the company's 10-year median is 3.38 vs. the industry median of 3.91, Genscript Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.91, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Current Ratio of 1.50 is 61.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Current Ratio is 1.50, which is 56% below median its own 10-year median of 3.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.48, compared to a current price of $1.60 — trading 35.5% below its estimated fair value. The current Current Ratio is 1.50, which is 56% below median its 10-year median of 3.38 and 61.6% below the Biotechnology industry median of 3.91. Genscript Biotech's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Current Ratio is 1.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued.
The current stock price of $1.60 is trading 35.5% below its estimated GF Value™ of $2.48.
GuruFocus considers Genscript Biotech to be Significantly Undervalued.
Key valuation signals for GNNSF:
Current Ratio: 1.50 (56% below median its 10-year median of 3.38)
GF Value™: $2.48 vs. price of $1.60 (35.5% below fair value)
Industry Position: 61.6% below the Biotechnology median (#1073 of 1411)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
66GF Score
Get the complete analysis for GNNSF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
